drugset / Trial / NCT06590857
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Timeline
- Start
- 2024-07-19
- Primary completion
- 2028-10
- Completion
- 2033-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACTINIUM DOTATATE | Other / unclassified | — | Intravenous |
| Background | Anastrozole | Other / unclassified | — | — |
| Background | Elacestrant | Other / unclassified | — | — |
| Background | Exemestane | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | — |
| Background | Imlunestrant | Small molecule | — | — |
| Background | Letrozole | Other / unclassified | — | — |
| Background | Tamoxifen | Small molecule | — | — |
| Background | vepdegestrant | Other / unclassified | — | — |